Glenmark Generics Gets U.S. FDA Approval For Two More Drugs
This article was originally published in PharmAsia News
India's Glenmark Generics received approval from U.S. FDA for its generic versions of Schering's Elocon (mometasone) and Bristol Myers Squibb's Metaglip (metformin hydrochloride). The approvals increase the portfolio of the Glenmark Pharmaceutical subsidiary to 32 generics on the U.S. market. CGL has another 35 generic applications in the mill at U.S. FDA. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.